Crinetics Pharmaceuticals: Once Daily, Oral Investigational Product Met Primary and Secondary Endpoints in Phase 3 Treatment of Acromegaly 

Crinetics Pharmaceuticals Once Daily, Oral Treatment for Acromegaly
Crinetics Pharmaceuticals (CRNX) announced that its oral and once daily investigational compound paltusotine achieved positive results by meeting the primary endpoint and all secondary endpoints of the Phase 3 PATHFNDR-1 study.  

PATHFNDR-1 study enrolled participants with acromegaly who were biochemically controlled on octreotide or lanreotide depot monotherapy. PATHFNDR-1 is . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.